Point-of-care rapid diagnostic test for Plasmodium vivax infection to be developed for in-field testing
Genedrive PLC (AIM:GDR) Genedrive® CYP2C19-ID Kit performance published
Superior performance to laboratory test and alternative available point of care platforms
Abingdon Health PLC (AIM:ABDX) Appointment of Chief Financial Officer
York, U.K. 19 December 2024: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract research (CRO) and contract development and manufacturing organisation (CDMO), announces the appointment of Tom Hayes as
Abingdon Health plc (AIM:ABDX) Contract win worth up to US$2million across 2025
Contract win: sexually transmitted disease tests Regulatory and clinical trials contract worth up to US$2million across 2025
Abingdon Health PLC (AIM: ABDX) Opening of US commercial office and laboratory
Abingdon Health plc (AIM: ABDX), a leading international medical device contract development and manufacturing organisation (CDMO), announces it has signed a lease to open a commercial office and laboratory in Madison,
Abingdon Health PLC (AIM: ABDX) Results of the Retail Offer
Completion of Retail Offer
Genedrive (AIM:GDR) shares fall 10% following CEO departure
Genedrive PLC (AIM: GDR) shares dropped 10% after the announcement that CEO James Cheek has left the company by mutual agreement.
Genedrive PLC (AIM: GDR) NICE recommends CYP2C19-ID Kit in final guidance
NICE recommends the Genedrive® CYP2C19-ID Kit in final guidance Genedrive® CYP2C19-ID test chosen as the preferred platform for point-of-care genotype testing prior to clopidogrel treatment for stroke patients in the
Genedrive PLC (AIM:GDR) Breakthrough Device Designation from the U.S. FDA
genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company, is pleased to announce that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) for the Genedrive® MT-RNR1
Abingdon Health PLC (AIM:ABDX) Annual Revenue Growth of 52%, Cashflow Positive in Q4
The board anticipates continued solid revenue growth in FY 2025
Genedrive PLC (AIM:GDR) Initial orders of the Genedrive MT-RNR1 Products
Initial orders of the Genedrive MT-RNR1 Products for new sites in the UK
Genedrive PLC (AIM:GDR) Proposed REX Retail Offer
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces its intention to raise funds by means of a proposed retail offer via the Retail Capital Markets ‘REX’ portal (the